YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells

被引:1
|
作者
Nakajima, Maako [1 ]
Tanaka, Kentaro [1 ]
Yoneshima, Yasuto [1 ]
Yamashita, Sho [1 ]
Shibahara, Daisuke [1 ]
Iwama, Eiji [1 ]
Okamoto, Isamu [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, 3-1-1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan
基金
日本学术振兴会;
关键词
Yes-associated protein (YAP); Epidermal growth factor (EGF); Epidermal growth factor receptor (EGFR); Non-small cell lung cancer; Apoptosis; Hippo pathway; GROWTH-FACTOR RECEPTOR; HIPPO PATHWAY; MECHANISMS; MUTATIONS;
D O I
10.1016/j.bbrc.2023.09.067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mechanisms underlying the growth and survival of non-small cell lung cancer (NSCLC) cells positive for activating mutations of the epidermal growth factor receptor gene (EGFR) have remained unclear. We here examined the functional relation between such mutant forms of EGFR and Yes-associated protein (YAP), a transcriptional coactivator of the Hippo signaling pathway that regulates cell proliferation and survival. Under the condition of serum deprivation, epidermal growth factor (EGF) induced activation of YAP in NSCLC cell lines positive for mutated EGFR but not in those wild type (WT) for EGFR. Similar EGF-induced activation of YAP was apparent in A549 lung cancer cells forcibly expressing mutant EGFR but not in those overexpressing the WT receptor. Furthermore, EGF induced apoptotic cell death in serum-deprived A549 cells overexpressing the WT form of EGFR but not in those expressing mutant EGFR, and knockdown of YAP rendered the latter cells sensitive to this effect of EGF. Our results thus suggest that activation of YAP mediates resistance of EGFR-mutated NSCLC cells to EGF-induced apoptosis and thereby contributes specifically to the survival of such cells.
引用
收藏
页码:120 / 126
页数:7
相关论文
共 50 条
  • [21] Tumor Microenvironment Remodeling Contributes to the Resistance to EGFR-TKI in EGFR-mutated Non-small Cell Lung Cancer
    Song, X.
    Zhou, C.
    Wu, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S362 - S362
  • [22] Aumolertinib as adjuvant therapy in postoperative EGFR-mutated non-small cell lung cancer
    Zhang, Q.
    He, C.
    He, T.
    Wang, Y.
    Lv, W.
    Hu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S73 - S73
  • [23] Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer
    Felip, Enriqueta
    Metro, Giulio
    Soo, Ross A.
    Wolf, Juergen
    Solomon, Benjamin J.
    Tan, Daniel S. W.
    Ardizzoni, Andrea
    Lee, Dae Ho
    Sequist, Lecia V.
    Barlesi, Fabrice
    Ponce-Aix, Santiago
    Abreu, Delvys Rodriguez
    Campelo, Maria Rosario Garcia
    Sprauten, Mette
    Djentuh, Leslie O'Sullivan
    Smith, Nathalie
    Jary, Aline
    Belli, Riccardo
    Glaser, Sabine
    Zou, Mike
    Cui, Xiaoming
    Giovannini, Monica
    Yang, James Chih-Hsin
    EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [24] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [25] Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
    Bhandari, Shruti
    Dunlap, Neal
    Kloecker, Goetz
    JOURNAL OF THORACIC DISEASE, 2021, 13 (05) : 3230 - 3234
  • [26] Deciphering the Characterization of Tumor Microenvironment in EGFR-Mutated Non-Small Cell Lung Cancer
    Qiao, M.
    Jiang, T.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S182 - S183
  • [27] Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
    Steendam, Christi M. J.
    Veerman, G. D. Marijn
    Pruis, Melinda A.
    Atmodimedjo, Peggy
    Paats, Marthe S.
    van der Leest, Cor
    von der Thusen, Jan H.
    Yick, David C. Y.
    Oomen-de Hoop, Esther
    Koolen, Stijn L. W.
    Dinjens, Winand N. M.
    van Schaik, Ron H. N.
    Mathijssen, Ron H. J.
    Aerts, Joachim G. J. V.
    Dubbink, Hendrikus Jan
    Dingemans, Anne-Marie C.
    CANCERS, 2020, 12 (11) : 1 - 17
  • [28] Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)
    Thamlikitkul, Lucksamon
    Manocheewa, Siriphan
    Limjiasahapong, Suphitcha
    Wanichthanarak, Kwanjeera
    Panya, Atikorn
    Poungvarin, Naravat
    Pomyen, Yotsawat
    Khoomrung, Sakda
    CANCER RESEARCH, 2024, 84 (06)
  • [29] RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer
    Yun, N.
    Naqib, A.
    Borgia, J. A.
    Fidler, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S458 - S459
  • [30] RNA sequencing to characterize pathways in EGFR-mutated non-small cell lung cancer
    Yun, Nicole
    Naqib, Ankur D.
    Borgia, Jeffrey Allen
    Batus, Marta
    Fidler, Mary Jo J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)